Since the publication of our previous paper, studies targeting β-catenin using a small molecule inhibitor ICG001, or knocking down LEF1, have resulted in the reversal of Lenvatinib resistance in hepatocellular carcinoma cells [63]. This evidence concerns the gene LEF1 and hepatocellular carcinoma.